Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
Immunotherapy: reshape the tumor immune microenvironment
B Lv, Y Wang, D Ma, W Cheng, J Liu, T Yong… - Frontiers in …, 2022 - frontiersin.org
Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …
The interactions between these components, which are divided into anti-tumor and pro …
Challenges in glioblastoma research: focus on the tumor microenvironment
Glioblastoma (GBM) is the most deadly type of malignant brain tumor, despite extensive
molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has …
molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has …
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
K Li, H Shi, B Zhang, X Ou, Q Ma, Y Chen… - Signal transduction and …, 2021 - nature.com
Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature
myeloid cells with immunosuppressive effects, which undergo massive expansion during …
myeloid cells with immunosuppressive effects, which undergo massive expansion during …
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Q Peng, X Qiu, Z Zhang, S Zhang, Y Zhang… - Nature …, 2020 - nature.com
Immune checkpoint blockade therapies have shown clinical promise in a variety of cancers,
but how tumor-infiltrating T cells are activated remains unclear. In this study, we explore the …
but how tumor-infiltrating T cells are activated remains unclear. In this study, we explore the …
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
The circadian clock is a critical regulator of immunity, and this circadian control of immune
modulation has an essential function in host defense and tumor immunosurveillance. Here …
modulation has an essential function in host defense and tumor immunosurveillance. Here …
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations
Melanoma, a skin cancer associated with high mortality rates, is highly radio-and
chemotherapy resistant but can also be very immunogenic. These circumstances have led to …
chemotherapy resistant but can also be very immunogenic. These circumstances have led to …
PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness
PARP inhibitors (PARPi) have shown remarkable therapeutic efficacy against BRCA1/2-
mutant cancers through a synthetic lethal interaction. PARPi exert their therapeutic effects …
mutant cancers through a synthetic lethal interaction. PARPi exert their therapeutic effects …
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Q Tang, Y Chen, X Li, S Long, Y Shi, Y Yu… - Frontiers in …, 2022 - frontiersin.org
Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …